Oramed Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Si prevede che gli utili di Oramed Pharmaceuticals diminuiranno del 104.1% all'anno, mentre si prevede che il fatturato annuo crescerà del 256.9% all'anno. Si prevede che l'EPS diminuirà del 104.4% all'anno.

Informazioni chiave

-104.1%

Tasso di crescita degli utili

-104.4%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	24.0%
Tasso di crescita dei ricavi	256.9%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	02 Dec 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Aug 24

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

May 03

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Dec 22

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Feb 23

Oramed And The Hurdles Of Developing Oral Insulin

Dec 23

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Nov 02

Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress

Oct 04

We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

Aug 24

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Jul 21

Oramed reaches 50% enrollment in late-stage oral insulin study

Jun 08

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Apr 06

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:ORMP - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2025	1	-8	N/A	N/A	2
12/31/2024	N/A	-10	N/A	N/A	2
9/30/2024	N/A	4	-8	-8	N/A
6/30/2024	N/A	21	-2	-2	N/A
3/31/2024	1	10	-6	-6	N/A
12/31/2023	1	6	-11	-10	N/A
9/30/2023	2	-16	-17	-17	N/A
6/30/2023	3	-20	-19	-18	N/A
3/31/2023	3	-30	-25	-24	N/A
12/31/2022	3	-37	-28	-28	N/A
9/30/2022	3	-46	-39	-39	N/A
6/30/2022	3	-46	-43	-43	N/A
3/31/2022	3	-40	-39	-39	N/A
12/31/2021	3	-35	-33	-33	N/A
11/30/2021	3	-25	-22	-22	N/A
8/31/2021	3	-22	-22	-21	N/A
5/31/2021	3	-18	-18	-17	N/A
2/28/2021	3	-15	-16	-15	N/A
12/31/2020	3	-22	-26	-25	N/A
11/30/2020	3	-15	-16	-16	N/A
8/31/2020	3	-12	-13	-12	N/A
5/31/2020	3	-11	-13	-13	N/A
2/29/2020	3	-13	-14	-14	N/A
11/30/2019	3	-13	-12	-12	N/A
8/31/2019	3	-14	-13	-13	N/A
5/31/2019	3	-15	-14	-14	N/A
2/28/2019	3	-15	-14	-14	N/A
11/30/2018	3	-14	-16	-16	N/A
8/31/2018	2	-13	N/A	-15	N/A
5/31/2018	2	-12	N/A	-12	N/A
2/28/2018	2	-10	N/A	-11	N/A
11/30/2017	2	-10	N/A	-10	N/A
8/31/2017	2	-10	N/A	-6	N/A
5/31/2017	2	-13	N/A	3	N/A
2/28/2017	2	-13	N/A	3	N/A
11/30/2016	1	-11	N/A	8	N/A
8/31/2016	1	-11	N/A	5	N/A
5/31/2016	0	-8	N/A	-3	N/A
2/29/2016	0	-8	N/A	-2	N/A
11/30/2015	N/A	-8	N/A	-6	N/A
8/31/2015	N/A	-7	N/A	-5	N/A
5/31/2015	N/A	-7	N/A	-5	N/A
2/28/2015	N/A	-7	N/A	-5	N/A
11/30/2014	N/A	-6	N/A	-5	N/A
8/31/2014	N/A	-6	N/A	-4	N/A
5/31/2014	N/A	-5	N/A	-4	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che gli utili di ORMP diminuiranno nei prossimi 3 anni ( -104.1% all'anno).

Guadagni vs Mercato: Si prevede che gli utili di ORMP diminuiranno nei prossimi 3 anni ( -104.1% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di ORMP diminuiranno nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di ORMP ( 256.9% all'anno) crescerà più rapidamente del mercato US ( 9.2% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ORMP ( 256.9% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di ORMP è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/12/31 23:06
Prezzo dell'azione a fine giornata	2024/12/31 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Oramed Pharmaceuticals Inc. è coperta da 8 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Andrew D'Silva	B. Riley Securities, Inc.
Edward Nash	Canaccord Genuity
Charles Duncan	Cantor Fitzgerald & Co.

Oramed Pharmaceuticals Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus revenue estimates decrease by 50%

Consensus revenue estimates increase by 15%

Consensus EPS estimates fall by 50%

Consensus EPS estimates upgraded to US$0.34 loss

Consensus EPS estimates fall by 13%

Consensus EPS estimates upgraded to US$0.35 loss

Recent updates

New minor risk - Market cap size

Investor sentiment improves as stock rises 21%

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.

Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024

Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024

Consensus revenue estimates decrease by 50%

Consensus revenue estimates increase by 15%

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)

New minor risk - Market cap size

Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Consensus EPS estimates fall by 50%

Insufficient new directors

Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024

Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 3Q 2022)

New minor risk - Market cap size

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Consensus EPS estimates upgraded to US$0.34 loss

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Consensus EPS estimates fall by 13%

Consensus EPS estimates upgraded to US$0.35 loss

Price target decreased by 82% to US$2.40

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

President recently bought US$201k worth of stock

Independent Director recently bought US$142k worth of stock

Consensus EPS estimates upgraded to US$0.59 loss

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 23% to US$15.16

Price target decreased to US$21.67

Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Price target decreased to US$28.67

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality

Oramed Pharmaceuticals Inc. Reports Positive Top-Line Results from Phase 2 Nash Trial with its ORMD-0801, Oral Insulin Candidate

Oramed to hand Korean rights for insulin capsule

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Oramed Reaches 50% Enrollment in Its Second Phase 3 Oral Insulin Trial

High number of new and inexperienced directors

Oramed to report early-stage trial data for oral COVID-19 shot in 3Q

Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Oramed Pharmaceuticals Inc., Annual General Meeting, Jun 30, 2022

Oramed Pharmaceuticals Inc. Appoints Anne Peters to Its Scientific Advisory Board

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Oramed Pharmaceuticals Inc. Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study Ora-D-013-1

Price target increased to US$32.50

Oramed And Oral Insulin: Can This Small Company Really Do It?

Oramed Pharmaceuticals Inc. Grants NASH Patent in Europe

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Independent Chairman of the Board recently sold US$94k worth of stock

Consensus forecasts updated

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Oramed And The Hurdles Of Developing Oral Insulin

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral Covid-19 Vaccine Trial in South Africa

Full year 2021 earnings: EPS and revenues miss analyst expectations